Rising Prevalence of Genetic Disorders to Drive Global Enzymatic DNA Synthesis Market
According to our new research study on “Enzymatic DNA Synthesis Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product Type, Application, Technology, and End User,” the enzymatic DNA synthesis market is expected to grow from US$ 240.96 million in 2022 to US$ 2,244.88 million by 2028; it is estimated to record a CAGR of 45.1% during 2022–2028. Key factors driving the growth of this market are the rising prevalence of genetic disorders and the surging number of product launches.
Down syndrome, autism spectrum disorder, cancer, diabetes, cystic fibrosis, and sickle cell anemia are a few of the commonly known genetic disorders. Per the Global Genes, more than 10,000 different genetic and rare diseases have been identified, and ~400 million people suffer from rare diseases. Some genetic disorders cause symptoms at birth, while others develop over time. The global burden of genetic diseases appears to be increasing. According to the National Center for Biotechnology Information (NCBI), a US-based medical organization, as of November 2021, genetic disorders were identified in 9.4% of pediatric patients, with 44.7% being critically ill newborns. In addition, 13.17 million patients in the US suffer from unique genetic disorders. According to the Centers for Disease Control and Prevention (CDC) 2022 report, sickle cell disease affects ~100,000 Americans, and it occurs in 1 in 356 African American births. Cystic fibrosis, another common genetic disease worldwide, affects ~30,000 people in the US, and ~1,000 new cases are treated annually. Enzymatic DNA synthesis is a well-established DNA synthesis technique useful in synthetic biology, genetic engineering, and therapeutic antibody studies. In conjunction with enzymatic assays, DNA synthesis shows greater diagnostic possibilities. This method provides important information about people at risk and helps them make important decisions regarding disease diagnosis and medication. Hence, with the rising prevalence of genetic disorders across the world, people are becoming more aware of the need for the early detection of these genetic flaws, which propels the growth of the enzymatic DNA synthesis market.
Telesis Bio Inc; Evonetix; Ansa Biotechnologies, Inc.; Camena Bio; GenScript Biotech Corp.; Molecular Assemblies; DNA Script; Touchlight; Synbio Technologies; and Twist Bioscience are among the leading companies operating in the enzymatic DNA synthesis market.
Based on product type, the enzymatic DNA synthesis market is segmented into custom DNA synthesis and DNA library synthesis. In terms of application, the market is segmented into synthetic biology, genetic engineering, therapeutic antibodies, vaccine design, and other applications. By end user, the enzymatic DNA synthesis market is divided into academic & research institutes, biotechnology & pharmaceutical companies, diagnostic laboratories, and others. Based on technology, the enzymatic DNA synthesis market is segmented into SOLA, CRISPR, PCR, and others. By geography, the enzymatic DNA synthesis market is segmented into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and Rest of APAC), the Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of MEA), and South & Central America (Brazil, Argentina, and Rest of South & Central America).
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com